Douglas Evan Godshall - 22 Jun 2021 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Reporting relationship: Director
Issuer ticker: EYPT
Reported as of: 22 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2021, 17:39:50 UTC
Prior SEC filing: 20 May 2021
Next SEC filing: 20 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Ron Honig, Attorney-in-Fact

Key filing fact

Douglas Evan Godshall filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 23 Jun 2021.

Key facts

This page summarizes Douglas Evan Godshall's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jun 2021, 17:39.

Change

Previous filing in this sequence was filed on 20 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EYPT transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +2,500
Change %: +45%
Price: $0.000000
Shares after: 8,016
Date: 22 Jun 2021
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EYPT transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: +2,500
Change %
Price: $0.000000^*
Shares after: 0
Date: 22 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price: $0.000000
Footnotes: F1, F2

EYPT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +11,000
Change %
Price: $0.000000
Shares after: 11,000
Date: 22 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,000
Exercise price: $13.13
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Douglas Evan Godshall is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021.

Footnote F2

The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.

Footnote F3

The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.